Eli Lilly’s shares have surged 750 per cent over five years. Novo Nordisk’s are up about 360 per cent in the same period.

Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

A little over a year ago, I took the stage at Livewire Live and made a 'shocking prediction' for 2024: we would witness “the ...

A recently released negative study by Novo Nordisk (NVO) on the differences between its own semaglutide and liraglutide ...

U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk ...

Speakers from across the care continuum will discuss legislative updates, glucagon-like peptide-1 (GLP-1) use for weight management, and more at this year’s AMCP Nexus.

The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.

WW stock popped after announcing a new compounded semaglutide product to benefit from the current shortage of weight loss ...

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.

The risk for kidney function decline is lower among new users of sodium glucose cotransporter-2 inhibitors (SGLT2i) vs glucagon-like peptide 1 receptor agonists (GLP-1RA), a real-world study of ...